InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Tuesday, 01/31/2023 11:17:39 AM

Tuesday, January 31, 2023 11:17:39 AM

Post# of 14953
COVIDROPS could not treat variants! But ABIVERTINIB, SOCAZOLIMAB and OVYDSO in China look good!
And SEMDEXA in US. All in 2023. All are highly partnerable world-wide for big upfront, milestone and royalty payments.

OVYDSO does more and faster than COVIDROPS and has huge market potential.

In fact all 4 have very large (multibillion!) potential. HAPPY 2023!

"The refusal of the real is the number one dogma of our time" Rene Girard